Pharsight

Tarpeyo patents expiration

TARPEYO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932 CALLIDITAS Compositions for the oral delivery of corticosteroids
May, 2029

(4 years from now)

US11896719 CALLIDITAS Pharmaceutical compositions
Jan, 2043

(18 years from now)

Tarpeyo is owned by Calliditas.

Tarpeyo contains Budesonide.

Tarpeyo has a total of 2 drug patents out of which 0 drug patents have expired.

Tarpeyo was authorised for market use on 15 December, 2021.

Tarpeyo is available in capsule, delayed release;oral dosage forms.

Tarpeyo can be used as reduction in loss of kidney function and reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the formulation, reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression.

The generics of Tarpeyo are possible to be released after 23 January, 2043.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-389) Dec 15, 2028
Orphan Drug Exclusivity(ODE-464) Dec 20, 2030
New Product(NP) Dec 15, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 15 December, 2021

Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression; Reduction in loss of kidney function and reduction of proteinuri...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

TARPEYO family patents

Family Patents